CXCL8 and non-small cell lung carcinoma: Nineteen patients with NSCLC treated with nivolumab or pembrolizumab were included and it was found that responders had significantly decreasing levels of IL-8 between baseline and the first tumor evaluation while non-responders had significantly increasing levels of IL-8.